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Diabetic patients can be affected by a wide variety of neurological 
complications which may involve the peripheral or autonomic 
nervous system, or both. These complications significantly impair 
the quality of life of patients, with impact on morbidity and mortality 
outcomes.
Diabetic cachectic neuropathy, also called diabetic neuropathic 
cachexia, is a very rare neurological complication of diabetes.[1] 
It was first described by Ellenberg[2] in 1934. It is associated with 
poor diabetic control that presents with profound unintentional 
weight loss associated with an acute symmetrical painful peripheral 
neuropathy without weakness.[3]
Pain is characteristically burning in nature, with predominant 
lower-limb involvement and allodynia. The disorder affects both 
type 1 and type 2 diabetics and occurs irrespective of the duration of 
diabetes. Depression and, in males, impotence appear to be common, 
although other autonomic features can be present. 
Although a few case reports exist in the literature describing this 
condition, to the best of our knowledge, there has been no such 
report from our practice environment. This article serves to describe 
a very rare neurological complication of diabetes that highlights our 
diagnostic and management experience.
Case report
A 40-year-old female patient with diabetes of 12 years’ duration, 
with poor drug compliance and clinic follow-up, presented to us 
at the accident and emergency department of the University of 
Port Harcourt Teaching Hospital with a 4-month history of rapid 
progressive weight loss, burning sensations in the feet, abdominal 
swelling, and constipation with occasional episodes of epigastric pain. 
These were associated with generalised body weakness, tiredness, 
and postural dizziness with occasional episodes of falling. She also 
admitted to florid, itching, offensive vaginal discharge. In addition, 
she had frothy urine, intermittent episodes of retrosternal chest pain, 
palpitations, and symptoms of hyperglycaemia. Her obstetric history 
was significant: two previous stillbirths and one second-trimester 
intrauterine fetal death. She had a strong family history of diabetes. 
She had been amennorrhoeic for about 5 months.
On examination, she was chronically ill-looking with a body mass 
index of 17.1 kg/m2, grossly distended abdomen (initially mistaken 
for gravid abdomen). She had a tachycardia of 128 bpm; blood 
pressure measurements in the supine and standing positions were 
200/130 mmHg and 180/100 mmHg, respectively. Her apex beat was 
not displaced but she had a third heart sound with gallop rhythm. 
There were reduced breath sounds in both lung bases. Neurological 
examination revealed stocking-pattern loss of pain, temperature and 
light touch modalities. Vibration sensation was impaired up to the 
malleoli bilaterally, with impairment of joint position sense of both 
big toes. 
Her random blood sugar level was 16.4 mmol/L; glycosylated 
haemoglobin was 13.2% with a haematocrit of 33.0%. Renal indices, 
uric acid, liver function tests and fasting lipid profile were all 
within normal limits. Her urine was pale yellow and turbid. Urine 
microscopy showed 2 - 3 pus cells/high power field with yeast and 
epithelial cells. Urine culture yielded scanty growth of Staphylococcus 
aureus (sensitive to cefuroxime, ceftriazone and perfloxacin) and 
moderate growth of Candida albicans. An abdominal ultrasound 
scan showed distended bowel loops. Her liver, spleen and kidneys 
were not enlarged. There was no ascites. Pregnancy test was negative. 
Electrocardiogram showed tachycardia, left atrial enlargement and 
left ventricular hypertrophy. Chest radiography showed cardiome-
galy and unfolded aorta in keeping with hypertensive cardiovascular 
changes. A biothesiometer was used to determine her vibration 
perception threshold. This was obtained by taking the average of 
three readings (R) obtained by placing the probe at the right toe (R1), 
left toe (R2) and again at the right toe (R3). The values obtained were 
27 mV, 28 mV and 27 mV, respectively. The vibration perception 
threshold average was 27.3 mV.
Management consisted of optimising glycaemic control with regu-
lar insulin and blood pressure control with antihypertensive agents 
(lisinopril and amlodipine, both 10 mg daily). She also received 
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atorvastatin 10 mg daily, clopidogrel 75 mg daily and nystatin vaginal 
pessaries nocte (6 doses). Medication was initially carbamazepine 
controlled-release formulation 200 mg twice daily for her neuro-
pathic pain. This had little effect and was discontinued. She, however, 
obtained rapid relief and amelioration of her neuropathic lower-limb 
pain with the introduction of pregabalin at 75 mg twice daily. 
Discussion
Our patient had complications involving both her peripheral and 
autonomic nervous system. Our initial consideration, because of her 
distended abdomen, was that of a diabetic patient presenting with 
distal symmetrical peripheral neuropathy in pregnancy. However, 
abdominal distension was just one of the many features of autonomic 
neuropathy that she manifested. The others were constipation, tired-
ness and postural dizziness. Distended loops of bowel on abdominal 
ultrasonography are in keeping with autonomic neuropathy of the 
gastrointestinal tract. The marked postural drop in blood pressure 
(20/30 mmHg) is a feature of cardiovascular autonomic neuropathy. 
The presence of autonomic symptoms is poorly prognostic in these 
patients. 
The response of her neuropathic pain to pregabalin was dramatic. 
Pregabalin has been recommended as the first-line agent for the treat-
ment of diabetic peripheral neuropathic pain in most guidelines.[4,5]
The San Antonio Consensus Criteria[6]  are commonly used to define 
diabetic neuropathy for research purposes, and recommend at least 
one measurement in five different categories for the diagnosis of 
diabetic neuropathy. For clinical neuropathy, the guidelines require 
symptoms and signs, or one of these with abnormal testing, or 
autonomic testing. Subclinical neuropathy is identified by abnormal 
testing only. Biothesiometry is an easy and objectively quantifiable 
means of diagnosing neuropathy in diabetic patients. A vibration 
perception threshold average of ≥25 mV is diagnostic of neuropathy. 
We were unable to perform nerve conduction studies, considered the 
gold standard for neuropathy diagnosis, because of lack of availability.
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